- Home
- NXTC vs WATT Comparison
NXTC vs WATT Comparison
Compare NXTC & WATT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- WATT
- Stock Information
- Founded
- NXTC 2015
- WATT 2012
- Country
- NXTC United States
- WATT United States
- Employees
- NXTC N/A
- WATT N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- WATT Radio And Television Broadcasting And Communications Equipment
- Sector
- NXTC Health Care
- WATT Technology
- Exchange
- NXTC Nasdaq
- WATT Nasdaq
- Market Cap
- NXTC 9.3M
- WATT 9.1M
- IPO Year
- NXTC 2019
- WATT 2014
- Fundamental
- Price
- NXTC $0.43
- WATT $0.29
- Analyst Decision
- NXTC Strong Buy
- WATT Strong Buy
- Analyst Count
- NXTC 2
- WATT 2
- Target Price
- NXTC $3.50
- WATT $2.25
- AVG Volume (30 Days)
- NXTC 259.7K
- WATT 862.1K
- Earning Date
- NXTC 05-05-2025
- WATT 05-13-2025
- Dividend Yield
- NXTC N/A
- WATT N/A
- EPS Growth
- NXTC N/A
- WATT N/A
- EPS
- NXTC N/A
- WATT N/A
- Revenue
- NXTC N/A
- WATT $768,000.00
- Revenue This Year
- NXTC N/A
- WATT $1,028.91
- Revenue Next Year
- NXTC N/A
- WATT N/A
- P/E Ratio
- NXTC N/A
- WATT N/A
- Revenue Growth
- NXTC N/A
- WATT 62.02
- 52 Week Low
- NXTC $0.22
- WATT $0.12
- 52 Week High
- NXTC $1.82
- WATT $2.70
- Technical
- Relative Strength Index (RSI)
- NXTC 44.58
- WATT 48.95
- Support Level
- NXTC $0.22
- WATT $0.24
- Resistance Level
- NXTC $0.44
- WATT $0.28
- Average True Range (ATR)
- NXTC 0.06
- WATT 0.03
- MACD
- NXTC 0.02
- WATT 0.01
- Stochastic Oscillator
- NXTC 86.11
- WATT 91.24
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.